DZ-002 for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lymphoma+1 MoreDZ-002 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is to test the safety of DZ-002 and to see what dose is tolerated by patients with solid tumors. They will also assess how the drug works against tumors.

Eligible Conditions
  • Lymphoma
  • Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 7 Secondary · Reporting Duration: 24 months

24 months
Incidence and severity of treatment emergent adverse events (TEAEs)
MTD
Tumor response
56 days
AUC
Clearance
Cmax
Tmax
Volume of distribution
t1/2

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Dose escalation and cohort expansion Q1W
1 of 1

Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: DZ-002 · No Placebo Group · Phase 1

Dose escalation and cohort expansion Q1W
Drug
Experimental Group · 1 Intervention: DZ-002 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

Da Zen Theranostics IncLead Sponsor
Robert L De Jager, MDStudy DirectorDazen Theranostics

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are an adult with a hemoglobin level of 8.0 g/dL or higher.
You have measurable or evaluable disease by RECIST v 1.1, or PCWG3 for prostate cancer.
You have a histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid malignant tumor (including lymphoma; dose-escalation phase only) that has failed to respond to standard therapies.
You are a male or female patient age 18 or older.